

For Immediate Release

Ortho Regenerative Technologies Inc. Announces Receiving Key Patent Protecting Lead Product in the United States

Montreal, Québec, Canada, August [], 2016 - Ortho Regenerative Technologies Inc. (“Ortho” or the “Corporation”), a regenerative medicine company focused on products for repair of sports medicine injuries, announced today the issuance of a patent from the United States Patent and Trademark office entitled “Soluble Physiological Chitosan Formulations Combined with Platelet Rich Plasma (PRP) for Tissue Repair”. US Patent 9,427,469 covers 1) specific chitosan formulations together with platelet rich plasma; and 2) Use of those formulations for biological repair of tissue.

“The granting of this patent marks an important milestone for Ortho as it provides protection for our lead product candidate in the world’s largest sports medicine market,” said Edward C. Margerrison, PhD, President and CEO of Ortho.

Protected in the patent is the Corporation’s lead product candidate, Restore-R™, a proprietary biopolymer being developed to biologically repair shoulder rotator cuff injuries. Surgical attachment of the tendons, the current standard of care, usually fails to reduce pain and/or restore function because of inadequate biological healing. Currently no method or product provides biological healing of the tissue in this indication, and as a result, the failure rates of surgery are unacceptably high.

The new patent is the first of four (4) patent applications in the Corporation’s portfolio to issue. The patents and patent applications protect the Corporation’s proprietary product candidates and their use. These patent applications are currently pending in Canada, the EU, and other major market territories around the world.

About Restore-R.

Restore-R is a room temperature-stable biopolymer being developed to be used in surgical procedures to repair shoulder rotator cuff injuries. The patented biopolymer has been specifically designed and formulated to reduce the high failure rate of surgical repair of the rotator cuff in the shoulder. Restore-R is designed to work within the current standard of care in an orthopedic surgical suite without significant additional surgical time, at a price expected to fit into current payer payment paradigms in the US.

About Ortho Regenerative Technologies Inc.

Ortho Regenerative Technologies, Inc. (“Ortho”) is a biotechnology company developing its patented biopolymer product Restore-R™ to address an unmet medical need in the multi-billion dollar Sports Medicine market. Restore-R™ is being developed to biologically repair shoulder rotator cuff injuries, where surgical attachment of the tendons, the current standard of care, usually fails to reduce pain and/or restore function because of inadequate biological healing. Currently no method or product provides biological healing of the tissue in this indication, and as a result, the failure rates of surgery are

unacceptably high. Lack of biological repair of these tissues leads to reduced mobility, enduring pain, workplace absence, and expensive revision surgery. Restore-R™ has been designed as an add-on to currently existing surgical procedures to promote biological healing of the tissue and significantly reduce complications and failure rates.

Ortho's proprietary biopolymer technology platform, Restore™, has broad potential use for the development of multiple additional products addressing other unmet needs in ligament, tendon, and soft tissue repair. Subsequent indications include repair of the meniscus in the knee, other ligaments and tendons such as the ACL and the spinal disc.

Caution regarding forward-looking statements

This news release contains certain forward looking statements and forward looking information (collectively referred to herein as "forward looking statements") within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward looking statements. Forward looking information is often, but not always, identified by the use of words such as "could", "should", "can", "anticipate", "expect", "believe", "will", "may", "projected", "sustain", "continues", "strategy", "potential", "projects", "grow", "take advantage", "estimate", "well positioned" or similar words suggesting future outcomes. In particular, this news release may contain forward looking statements relating to future opportunities, business strategies, development and production plans and competitive advantages.

The forward looking statements regarding the Corporation are based on certain key expectations and assumptions of the Corporation concerning anticipated financial performance, business prospects, strategies, regulatory developments, exchange rates, tax laws, the sufficiency of budgeted capital expenditures in carrying out planned activities, the availability and cost of labour and services and the ability to obtain financing on acceptable terms and future costs and expenses being based on historical costs and expenses, adjusted for inflation, all of which are subject to change based on market conditions and potential timing delays. Although management of the Corporation consider these assumptions to be reasonable based on information currently available to them, they may prove to be incorrect.

By their very nature, forward looking statements involve inherent risks and uncertainties (both general and specific) and risks that forward looking statements will not be achieved. Undue reliance should not be placed on forward looking statements, as a number of important factors could cause the actual results to differ materially from the beliefs, plans, objectives, expectations and anticipations, estimates and intentions expressed in the forward looking statements, including among other things: inability of the Corporation to continue meet the listing requirements of stock exchanges and other regulatory requirements, general economic and market factors, including business competition, changes in government regulations or in tax laws; general political and social uncertainties; the actual results of research, development or operational activities; changes in project parameters as plans continue to be refined; lack of insurance; delay or failure to receive board or regulatory approvals; changes in legislation, affecting the Corporation; timing and availability of external financing on acceptable terms; and lack of qualified, skilled labour or loss of key individuals; as well as those factors detailed from time to time in the Corporation's interim and annual financial statements and management's discussion and analysis of those statements, along with the Corporation's annual information form, all of which are

filed and available for review on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list is not exhaustive.

The forward looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake and is not obligated to publicly update such forward looking statements to reflect new information, subsequent events or otherwise unless so required by applicable securities laws.

Inquiries

Edward Margerrison, PhD
President and CEO
Ortho Regenerative Technologies Inc,
margerrison@OrthoRTi.com
512-550-8005
www.orthorti.com